On August 26, 2024,
News source 〔Anue news〕：https://news.cnyes.com/news/id/5696288
ReBlood, a multinational corporation, announced its entry into the AI wave, investing NT$10 million in the implementation of Yushan AI. This offline on-premise AI solution will be utilized in the future establishment of an automated production lab, front-end intelligent consulting services, and will also enhance the protection of member privacy and inheritance needs. This move marks a significant advancement in ReBlood’s technological innovation, aiming to strengthen its integration capabilities in the AI-driven medical and healthcare sectors.
Introduction and Mission of ReBlood Group
ReBlood Group was founded by CEO Sean Chen (Chen Guoxiang), who has long assisted enterprises in multinational planning and family succession. Faced with the challenges of health and aging succession across various industries, the group has integrated the latest biotechnology on a global scale. With the trust and support of many renowned corporate clients, ReBlood established its headquarters in Tainan, aiming to create a multinational group. The group is dedicated not only to advancing the application of cellular technology in preventive, precision, and regenerative medicine but also to building a personalized health platform that helps clients better understand and manage their health.
ReBlood’s mission goes beyond addressing human aging issues. From its inception, the company has focused on the sustainable inheritance of health for both people and the environment. In addition to establishing a comprehensive health platform, ReBlood Group also provides high-end family financial integration planning for its members. The group responds to various investment issues by aligning with the United Nations’ Sustainable Development Goals (SDGs). This includes investments in green energy, with the aim of creating projects that enhance longevity while promoting carbon reduction, shared prosperity, and overall well-being.
Biotechnology in the Age of AI: Opportunities and Challenges with Privacy Protection as a Key
With the rise of the AI era, Coherent Market Insight predicts that the global artificial intelligence biotechnology market value will reach USD 2.1 billion in 2024 and USD 7.11 billion by 2031, with a compound annual growth rate (CAGR) of 19% from 2024 to 2031. AI has the potential to fundamentally change various processes in biotechnology, lowering manufacturing costs and benefiting the flourishing of precision medicine. However, concerns about how to manage personal data privacy have emerged.
Currently, most generative AI services on the market rely on large language models provided by major companies like Google, Meta, and Microsoft, typically accessed through cloud services. While this approach offers high accuracy and saves considerable training and development time, it may pose risks to privacy breaches for sensitive information in areas such as health and finance. Consequently, companies are tending to stick to alternatives — on-premise servers to ensure data security.
The recently procured Yushan AI is an advanced artificial intelligence system designed for big data analysis and machine learning. Developed by a leading Taiwanese AI company, Yushan AI features high flexibility and scalability. Its powerful processing capabilities and advanced algorithms can rapidly analyze large datasets, providing precise and in-depth insights crucial for analyzing and predicting AI healthcare data. By integrating with ReBlood’s existing technological infrastructure, Yushan AI will process vast amounts of complex data locally, offering deeper health insights and predictions.
ReBlood Group Introduces Yushan AI: Enhancing Privacy Protection and Advancing Precision Medicine
The name ReBlood Group originates from its process of selecting the youngest cells from autologous blood, cultivating and amplifying them, and then reinfusing them back into the body. This practice, which has demonstrated significant health benefits and self-healing in clinical settings, inspired the company’s name.
ReBlood CEO Sean stated, “Introducing Yushan AI is a pivotal step in our strategic development towards a public listing. This will significantly enhance the privacy protection of health and financial information for our premium members, allowing us to deliver higher-quality, precise services.” He further emphasized that this investment in offline AI will strengthen the group’s market leadership in “regenerative medical biotechnology services” and “integrated green e-commerce models.”
Chairman Zhang Yifa of Yushan.AI Corp and Inkstone Capital remarked, “Yushan AI is a US and Taiwan-based AI company specializing in large language models. Through this collaboration with ReBlood, we aim to further drive the development of AI technology and bring innovation and transformation to the healthcare sector.”
In summary, ReBlood Group’s investment of over NT$10 million in integrating Yushan AI demonstrates its strong commitment to advancing technological progress and improving product service quality and privacy protection. This integration is just the beginning. In the future, with the further development of artificial intelligence technology, ReBlood plans to invest additional resources and funds, aiming to achieve more breakthroughs in health data analysis and provide more advanced and reliable health management solutions for users worldwide.
About ReBlood
ReBlood Group is a service company focused on providing innovative solutions to address the global challenges of aging populations, declining birth rates, and the associated health, longevity, financial, and derivative issues. By integrating services and solutions related to health management, including preventive medicine, precision medicine, and regenerative medicine, ReBlood is dedicated to helping clients and their families achieve the vision of “Health, Happiness, and Longevity.”
About Yushan.AI Corp.
Yushan.AI is a technology company specializing in providing on-premise AI solutions based on large language Transformer models. By combining advanced AI technology with local processing capabilities, Yushan AI is committed to offering secure and reliable AI service solutions that address critical issues such as information security that may arise with online AI.
About Inkstone Capital
Inkstone Capital is a venture capital firm focused on investing in high-tech, high-growth, and ESG-related companies. Its portfolio includes Aimfinity Investment Corp. I, a Nasdaq-listed company (stock code: AIMAU), Greentek Innovation Inc., an innovative paper-based packaging products company, YuShan AI, an AI company specializing in large language models, and Inkstone Insurance Brokers.